Cargando…
Checkpoint Inhibitors in Acute Myeloid Leukemia
The prognosis of acute myeloid leukemia (AML) remains unsatisfactory. Among the reasons for the poor response to therapy and high incidence of relapse, there is tumor cell immune escape, as AML blasts can negatively influence various components of the immune system, mostly weakening T-cells. Since l...
Autores principales: | Damiani, Daniela, Tiribelli, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295997/ https://www.ncbi.nlm.nih.gov/pubmed/37371818 http://dx.doi.org/10.3390/biomedicines11061724 |
Ejemplares similares
-
ABCG2 in Acute Myeloid Leukemia: Old and New Perspectives
por: Damiani, Daniela, et al.
Publicado: (2023) -
Present and Future Role of Immune Targets in Acute Myeloid Leukemia
por: Damiani, Daniela, et al.
Publicado: (2022) -
Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019) -
Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia
por: Gurska, Lindsay, et al.
Publicado: (2023) -
Impact of Concomitant Aberrant CD200 and BCL2 Overexpression on Outcome of Acute Myeloid Leukemia: A Cohort Study from a Single Center
por: Tiribelli, Mario, et al.
Publicado: (2021)